Pathological studies on the protective effect of a macrolide antibiotic, roxithromycin, against sulfur mustard inhalation toxicity in a rat model

Toxicologic Pathology

Volumn 39, Issue 7, 2011, Pages 1056-1064

  Gao, Xiugong ^a   Anderson, Dana R ^b   Brown, Ammon W ^a   Lin, Hsiuling ^a   Amnuaysirikul, Jack ^a   Chua, Aileen L ^a   Holmes, Wesley W ^b   Ray, Prabhati ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

Author keywords

macrolide antibiotic; pathology; rat lung; respiratory injury; roxithromycin; sulfur mustard; toxicity

Indexed keywords

MACROLIDE; MUSTARD GAS; ROXITHROMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; HISTOPATHOLOGY; LUNG INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY EPITHELIUM;

ACUTE LUNG INJURY; ANIMALS; BRONCHI; DISEASE MODELS, ANIMAL; HISTOCYTOCHEMISTRY; INHALATION EXPOSURE; MALE; MUSTARD GAS; PROTECTIVE AGENTS; PULMONARY ALVEOLI; RATS; RESEARCH DESIGN; ROXITHROMYCIN; TRACHEA;

EID: 82355191816     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623311422079     Document Type: Article

References (26)

1. Amir A., Chapman S., Kadar T., Gozes Y., Sahar R., Allon N.. Sulfur mustard toxicity in macrophages: Effect of dexamethasone. J Appl Toxicol. 2000 ; 20: S51-8
2. Anderson D. R., Byers S. L., Vesely K. R.. Treatment of sulfur mustard (HD)-induced lung injury. J Appl Toxicol. 2000 ; 20: S129-32
3. Anderson D. R., Yourick J. J., Moeller R. B., Petrali J. P., Young G. D., Byers S. L.. Pathologic changes in rat lungs following acute sulfur mustard inhalation. Inhal Toxicol. 8: 285-97
4. Bryskier A., Neu H. C., Butzler J. P., Tulkens P. M. Macrolides: Chemistry, Pharmacology and Clinical Uses. Paris: Blackwell Publishers ; 1993 :
5. Cowan F. M., Broomfield C. A.. Putative roles of inflammation in the dermatopathology of sulfur mustard. Cell Biol Toxicol. 1993 ; 9: 201-13
6. Cowan F. M., Broomfield C. A., Lenz D. E., Smith W. J.. Putative role of proteolysis and inflammatory response in the toxicity of nerve and blister chemical warfare agents: Implications for multi-threat medical countermeasures. J Appl Toxicol. 2003 ; 23: 177-86 (Pubitemid 36701196)
7. Eisenmenger W., Drasch G., von Clarmann M., Kretschmer E., Roider G.. Clinical and morphological findings on mustard gas [bis(2-chloroethyl)sulfide] poisoning. J Forensic Sci. 1991 ; 36: 1688-698
8. Emad A., Rezaian G. R.. The diversity of the effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure: Analysis of 197 cases. Chest. 1997 ; 112: 734-38 (Pubitemid 27410711)
9. Gao X., Ray R., Xiao Y., Barker P. E., Ray P.. Inhibition of sulfur mustard-induced cytotoxicity and inflammation by the macrolide antibiotic roxithromycin in human respiratory epithelial cells. BMC Cell Biol. 2007 ; 8: 17
10. Gao X., Ray R., Xiao Y., Ishida K., Ray P.. Macrolide antibiotics improve chemotactic and phagocytic capacity as well as reduce inflammation in sulfur mustard-exposed monocytes. Pulm Pharmacol Ther. 2010 ; 23: 97-106
11. Gao X., Ray R., Xiao Y., Ray P.. Suppression of inducible nitric oxide synthase expression and nitric oxide production by macrolide antibiotics in sulfur mustard-exposed airway epithelial cells. Basic Clin Pharmacol Toxicol. 2008 ; 103: 255-61
12. Washington, D.C.: National Academy Press ; 1996 :
13. Jain R., Danziger L. H.. The macrolide antibiotics: A pharmacokinetic and pharmacodynamic overview. Curr Pharm Des. 2004 ; 10: 3045-053 (Pubitemid 39242900)
14. Kehe K., Balszuweit F., Steinritz D., Thiermann H.. Molecular toxicology of sulfur mustard-induced cutaneous inflammation and blistering. Toxicol. 2009 ; 263: 12-9
15. Kehe K., Szinicz L.. Medical aspects of sulphur mustard poisoning. Toxicol. 2005 ; 214: 198-209 (Pubitemid 41406260)
16. Kimura N., Nishioka K., Nishizaki K., Ogawa T., Naitou Y., Masuda Y.. Clinical effect of low-dose, long-term roxithromycin chemotherapy in patients with chronic sinusitis. Acta Med Okayama. 1997 ; 51: 33-7 (Pubitemid 127457674)
17. Konno S., Asano K., Kurokawa M., Ikeda K., Okamoto K., Adachi M.. Antiasthmatic activity of a macrolide antibiotic, roxithromycin: Analysis of possible mechanisms in vitro and in vivo. Int Arch Allergy Immunol. 1994 ; 105: 308-16 (Pubitemid 24318005)
18. Markham A., Faulds D.. Roxithromycin: An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994 ; 48: 297-326 (Pubitemid 24260359)
19. Papirmeister B., Fiester A. J., Robinson S. I., Ford R. D. Medical Defense against Mustard Gas: Toxic Mechanisms and Pharmacological Implications. Boca Raton, FL.: CRC Press ; 1991 :
20. Periti P., Mazzei T., Mini E., Novelli A.. Adverse effects of macrolide antibacterials. Drug Saf. 1993 ; 9: 346-64 (Pubitemid 23325295)
21. Rubin B. K.. Immunomodulatory properties of macrolides: Overview and historical perspective. Am J Med. 2004 ; 117: 2S - 4S
22. Smith K. J., Hurst C. G., Moeller R. B., Skelton H. G., Sidell F. R.. Sulfur mustard: Its continuing threat as a chemical warfare agent, the cutaneous lesions induced, progress in understanding its mechanism of action, its long-term health effects, and new developments for protection and therapy. J Am Acad Dermatol. 1995 ; 32: 765-76
23. Suzuki H., Ikeda K., Honma R., Gotoh S., Oshima T., Furukawa M., Takasaka T.. Prognostic factors of chronic rhinosinusitis under long-term low-dose macrolide therapy. ORL J Otorhinolaryngol Relat Spec. 2000 ; 62: 121-27 (Pubitemid 30248562)
24. Suzuki H., Shimomura A., Ikeda K., Oshima T., Takasaka T.. Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients. Tohoku J Exp Med. 1997 ; 182: 115-24 (Pubitemid 27435251)
25. Szinicz L.. History of chemical and biological warfare agents. Toxicol. 2005 ; 214: 167-81 (Pubitemid 41406257)
26. Young R. A., Gonzalez J. P., Sorkin E. M.. Roxithromycin: A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1989 ; 37: 8-41 (Pubitemid 19086730)